Abbreviations:BRVO (branch retinal vein occlusion), ICC (intraclass correlation coefficient), MA (microaneurysms), ME (macular edema), NPA (non-perfused area), NV (neovascularization), UW-FA (ultra-widefield fluorescein angiography), VA (visual acuity), VEGF (vascular endothelial growth factor)
Ogura Y, Kondo M, Kadonosono K, Shimura M, Kamei M, Tsujikawa A. Current practice in the management of branch retinal vein occlusion in Japan: survey results of retina specialists in Japan [published correction appears in Jpn J Ophthalmol. 2020;64:321]. Jpn J Ophthalmol. 2019;63:365-373.
- Microaneurysms cause refractory macular edema in branch retinal vein occlusion.Sci Rep. 2016; 6: 29445
- Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion.Ophthalmology. 2016; 123: 625-634.e1
- Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial.JAMA Ophthalmol. 2021; 139: 701-712
- Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.Ophthalmology. 1996; 103: 1820-1828
- Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.Invest Ophthalmol Vis Sci. 2009; 50: 1025-1032
- Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial.Arch Ophthalmol. 1986; 104: 34-41
Publication stageIn Press Journal Pre-Proof
Meeting Presentation: None
Financial Support: Kotaro Tsuboi received personal fees from Bayer, Novartis Pharma, Santen, and Alcon Japan outside of the submitted work. Motohiro Kamei received grants from Alcon Japan, Alcon Pharmaceuticals, AMO Japan, Bayer, Chuo Sangio, HANDAYA, HOYA Surgical Optics, Kowa, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Santen, Senju, and Wakamoto Pharma and received personal fees from AbbVie, Alcon Japan, Bayer, HOYA Surgical Optics, Johnson & Johnson, Leica Microsystems, Nikon Healthcare Japan, Novartis Pharma, Pfizer Japan, Santen, Senju, and Wakamoto Pharma. Motohiro Kamei received other fees from Astellas Pharma, HOYA Surgical Optics, and Senju outside of the submitted work. There are no other disclosures to report.
Conflicts of interest: The authors declare they have no conflicts of interest.
Address for reprints: Kotaro Tsuboi, Department of Ophthalmology, Aichi Medical University, Nagakute, 4801195, Japan, Phone number: +81-561-62-3311, Email address: email@example.com .